ArticleMethods (San Diego, Calif.)2026
Comprehensive evaluation of reference miRNA for extracellular miRNA quantification in CKD.
Article in Methods (San Diego, Calif.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
MicroRNAs (miRNAs) are promising biomarkers and therapeutic targets; however, reliable extracellular miRNA quantification by RT-qPCR depends on appropriate normalization, and no universal endogenous reference has been established. This study aimed to identify optimal endogenous control for extracellular miRNA analyses. Candidate reference miRNAs were first identified through next-generation sequencing of plasma (n = 289) and urine (n = 109) using samples from the Chronic Renal Insufficiency Cohort (CRIC). Candidates were prioritized using NormFinder algorithm combined with complementary stability metrics (including biological coefficient of variation, expression difference, mean expression, proportion of detectable samples) and evidence from literature. The top candidate miRNAs identified in discovery phase were subsequently validated by RT-qPCR in 250 plasma and 205 urine samples randomly selected from the remaining CRIC participants. Both descriptive statistical analysis and NormFinder identified hsa-miR-126-3p, hsa-miR-30e-5p, and hsa-miR-24-3p as most stably expressed miRNAs in plasma, whereas members of let-7 family, hsa-miR-423-5p, and hsa-miR-16-5p showed the highest stability in urine. RT-qPCR validation showed that hsa-miR-24-3p was detectable in 97% of the validation cohort and showed significant superior expression stability (p < 0.0001), identifying it as the most robust endogenous reference miRNA for plasma normalization. The addition of hsa-miR-30e-5p moderately improves expression stability if dual-reference normalization is considered. In urine, candidate reference miRNAs showed low detectability; although hsa-miR-16-5p was more stable than hsa-miR-423-5p, neither is recommended for routine normalization without substantial technical optimization. Overall, hsa-miR-24-3p represents a reliable and robust endogenous control for plasma miRNA normalization within this CKD cohort, whereas urinary miRNAs require rigorous, context-specific validation to ensure accurate and reproducible quantification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.